Femasys (FEMY)
(Delayed Data from NSDQ)
$1.27 USD
-0.06 (-4.51%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
FEMY 1.27 -0.06(-4.51%)
Will FEMY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for FEMY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FEMY
Femasys (FEMY) to Report Q3 Earnings: What's in the Cards?
Bears are Losing Control Over Femasys Inc. (FEMY), Here's Why It's a 'Buy' Now
FEMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Femasys Inc. (FEMY) Reports Q3 Loss, Lags Revenue Estimates
Voyager Therapeutics (VYGR) Beats Q3 Earnings and Revenue Estimates
Femasys Inc. (FEMY) Reports Q2 Loss, Tops Revenue Estimates
Other News for FEMY
Femasys Releases Updated Investor Presentation Information
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
Femasys CEO meets with members of Congress to raise awareness
Femasys: A Buy Rating on Innovative Reproductive Solutions and Market Expansion Potential
Femasys price target raised by $2 at H.C. Wainwright, here's why